BTIG analyst Mark Massaro lowered the firm’s price target on Adaptive Biotechnologies to $5 from $6 but keeps a Buy rating on the shares. The company’s strategic review concluded that it will make no material changes and instead will continue to operate both of its business segments internally, driving a 10% decline in the stock price yesterday, the analyst tells investors in a research note. Adaptive Biotechnologies acknowledged it did receive multiple offers for its MRD business from key strategic players, however the offers came in below its expectations and requirements, the firm notes. BTIG adds that the company has likely made the right decision, since it is is not that far away from achieving its goal to be adjusted EBITDA-positive, and the firm believes that at 1.7-times consensus 2025 revenue estimates, the stock is undervalued.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADPT:
- Adaptive Biotechnologies CFO Resigns, Successor Appointed
- Adaptive Biotechnologies to host business news update conference call
- Adaptive Biotechnologies Provides Strategic Review Update and Announces Preliminary First Quarter 2024 Revenue
- Adaptive Biotechnologies to Present at the TD Cowen 44th Annual Healthcare Conference
- Adaptive Biotechnologies price target lowered to $5 from $6 at Piper Sandler